Astellas Pharma Inc

Explore how Astellas Pharma’s $90 M and $120 M Mirabegron settlement deals boost U.S. exclusivity and fuel its oncology growth strategy.

Astellas Pharma’s first‑half earnings soar, doubling operating income and 106%‑boosting profit, prompting an upside‑revised outlook and a strategic focus on oncology & metabolic therapies.

Astellas Pharma Inc. has reported a profit increase in Q1 2025, driven by growth opportunities in oncology and cell therapy markets, positioning the company for continued success in the pharmaceutical industry.

Astellas Pharma Inc. has seen a 4.19% increase in its stock price, reaching 8,588 €, reflecting investor confidence in the company’s strategic direction and commitment to advancing healthcare solutions.

Astellas Pharma Inc. continues to advance in the pharmaceutical industry with innovative treatments and research, despite current financial challenges.